Page 71 - PCC07

i
e
i
n
nP
Po
ol
ly
y
c
c
y
ys
s
t
t
i
ic
c
O
Ov
v
a
PCOS diagnosis
a
r
r
y
yS
Sy
yn
nd
d
r
ro
o
m
m
e
e
(
(
p
p
r
ro
o
j
je
e
c
ct
tn
nu
u
m
mb
be
er
rA
A
P
P
P
P1
1
0
07
78
8
Rotterdam diagnostic criteria requires two of:
1. Oligo‐ or anovulation;
2. Clinical and/or biochemical hyperandrogenism;
3. Polycystic ovaries; when 1 & 2 are not both present and exclusion of other aetiologies
NIH diagnostic criteria requires:
1. Oligo‐ or anovulation; and
2. Clinical and/or biochemical hyperandrogenism
3. Where diagnosis is unclear but features exist reassessment should be planned;
Exclusion of other aetiologies is needed
Teede et al Human Repro 2018, MJA 2011, Rotterdam HR 2003
T
T
h
h
i
i
s
sw
w
o
o
r
rk
ki
i
s
s
s
s
u
u
p
pp
p
o
o
r
r
t
t
e
e
d
db
b
y
yt
t
h
he
eN
N
H
H
M
MR
R
C
Cf
f
u
u
n
nd
d
e
e
d
d
C
C
e
e
n
n
t
t
r
r
e
ef
f
o
o
r
rR
Re
4
4
e
s
4
s
44
e
ea
4)
).
a
r
.
r
c
ch
h
E
Ex
x
c
c
e
el
ll
le
e
n
nc
ce
i
e
i
n
nP
Po
ol
l
y
y
c
cy
y
s
s
t
t
i
ic
c
O
O
v
va
ar
Other assessments for PCOS
• Metabolic screening
• Fasting lipids (or HbA1C/FG) 1‐3 yearly
• 75g OGTT (with any additional risk factors)
• Not insulin levels – assay variability & inaccuracy
• OSA
• Clinical screening
• Endometrial cancer
• Awareness of risk and prevention
r
y
yS
S
y
yn
nd
d
r
ro
o
m
m
e
e(
(
p
pr
r
o
o
j
j
e
e
c
ct
t
n
nu
um
mb
b
e
e
r
r
A
AP
PP
P
1
1
0
07
7
8
8
4
4
4
44
4)
).
.
ll
l
e
en
nc
c
e
Teede et al Human Reproduction 2018
T
Th
hi
is
s
w
w
o
o
r
rk
k
i
is
ss
su
u
p
p
p
po
o
r
r
t
te
e
d
db
by
yt
t
h
he
eN
NH
H
M
MR
R
C
Cf
fu
u
n
nd
d
e
ed
dC
Ce
e
n
n
t
t
r
r
e
ef
f
o
o
r
rR
Re
es
s
e
ea
a
r
rc
c
h
h
E
Ex
xc
ce
el
Page 64 of 196
PRECONGRESS COURSE 07 I BARCELONA, SPAIN – 1 JULY 2018 71
R o t t e r d a m/NIH
Adolescence